Triple-negative breast cancer (TNBC), one of the subtypes of breast cancer, accounts for 15–20% of all breast cancer cases [13], and is characterized by loss of the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [14]. This evidence concerns the gene ESR1 and breast carcinoma.